Letter: Intranuclear particles in hepatocytes of HBAg-positive blood-donors

Observation of a B_{c}^{*+} Meson with the ATLAS Detector.

Physical review letters·2026

Combination of ATLAS and CMS Searches for Higgs Boson Pair Production at sqrt[s]=13 TeV.

Physical review letters·2026

Measurement of Charged-Particle Production in sqrt[s_{NN}]=9.62 TeV Proton-Oxygen Collisions as a Probe of Cosmic-Ray Air Showers with the ATLAS Detector.

Physical review letters·2026

Measurements of Z-Boson Pair Entanglement in Decays of Higgs Bosons at the ATLAS Experiment.

Physical review letters·2026

Evidence of ZZγ Production with the ATLAS Detector.

Physical review letters·2026

Evidence of Nuclear Geometry-Driven Anisotropic Flow in O+O and Ne+Ne Collisions at sqrt[s_{NN}]=5.36 TeV.

Physical review letters·2026

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Lancet (London, England)·2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Lancet (London, England)·2026

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Lancet (London, England)·2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

Lancet (London, England)·2026

Study-Grouped Predictive Toxicology of In Vitro Polystyrene Micro- and Nanoplastic Cytotoxicity: Geometry-Derived Administered-Dose Metrics and a Nanoscale-Restricted Sensitivity Analysis.

Polymers·2026

Acid alone does not digest: a lesson from nineteenth-century stomach physiology.

Advances in physiology education·2026

The Impact of Pathogen Inactivation Technologies on Platelet Quality and Clot Formation.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie·2026

Capillary physics links HIV capsid geometry to nuclear pore translocation.

Proceedings of the National Academy of Sciences of the United States of America·2026

Identification of the Root Cause of Visible Particle Formation in a Therapeutic Monoclonal Antibody by LC-MS-Based Approaches.

Molecular pharmaceutics·2026

Individual-level health effects of living near a gas-fired "Peaker" power plant.

The journal of climate change and health·2026

Related Experiment Videos

Letter: Intranuclear particles in hepatocytes of HBAg-positive blood-donors

Related Concept Videos

Observation of a B_{c}^{*+} Meson with the ATLAS Detector.

Combination of ATLAS and CMS Searches for Higgs Boson Pair Production at sqrt[s]=13 TeV.

Measurement of Charged-Particle Production in sqrt[s_{NN}]=9.62 TeV Proton-Oxygen Collisions as a Probe of Cosmic-Ray Air Showers with the ATLAS Detector.

Measurements of Z-Boson Pair Entanglement in Decays of Higgs Bosons at the ATLAS Experiment.

Evidence of ZZγ Production with the ATLAS Detector.

Evidence of Nuclear Geometry-Driven Anisotropic Flow in O+O and Ne+Ne Collisions at sqrt[s_{NN}]=5.36 TeV.

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

Study-Grouped Predictive Toxicology of In Vitro Polystyrene Micro- and Nanoplastic Cytotoxicity: Geometry-Derived Administered-Dose Metrics and a Nanoscale-Restricted Sensitivity Analysis.

Acid alone does not digest: a lesson from nineteenth-century stomach physiology.

The Impact of Pathogen Inactivation Technologies on Platelet Quality and Clot Formation.

Capillary physics links HIV capsid geometry to nuclear pore translocation.

Identification of the Root Cause of Visible Particle Formation in a Therapeutic Monoclonal Antibody by LC-MS-Based Approaches.

Individual-level health effects of living near a gas-fired "Peaker" power plant.

Related Experiment Videos

Letter: Intranuclear particles in hepatocytes of HBAg-positive blood-donors

Related Concept Videos

Related Articles